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Abstract
Epithelial barriers have to constantly cope with both harmless and harmful stimuli. The epithelial barrier therefore
serves as a dynamic and not static wall to safeguard its proper physiological function while ensuring protection. This is
achieved through multiple defence mechanisms involving various cell types - epithelial and non-epithelial - that work
in an integrated manner to build protective barriers at mucosal sites. Damage may nevertheless occur, due to
pathogens, physical insults or dysregulated immune responses, which trigger a physiologic acute or a pathologic
chronic inﬂammatory cascade. Inﬂammation is often viewed as a pathological condition, particularly due to the
increasing prevalence of chronic inﬂammatory (intestinal) diseases. However, inﬂammation is also necessary for wound
healing. The aetiology of chronic inﬂammatory diseases is incompletely understood and identiﬁcation of the
underlying mechanisms would reveal additional therapeutic approaches. Resolution is an active host response to end
ongoing inﬂammation but its relevance is under-appreciated. Currently, most therapies aim at dampening
inﬂammation at damaged mucosal sites, yet these approaches do not efﬁciently shut down the inﬂammation process
nor repair the epithelial barrier. Therefore, future treatment strategies should also promote the resolution phase. Yet,
the task of repairing the barrier can be an arduous endeavour considering its multiple integrated layers of defence -
which is advantageous for damage prevention but becomes challenging to repair at multiple levels. In this review,
using the intestines as a model epithelial organ and barrier paradigm, we describe the consequences of chronic
inﬂammation and highlight the importance of the mucosae to engage resolving processes to restore epithelial barrier
integrity and function. We further discuss the contribution of pre-mRNA alternative splicing to barrier integrity and
intestinal homeostasis. Following discussions on current open questions and challenges, we propose a model in
which resolution of inﬂammation represents a key mechanism for the restoration of epithelial integrity and function.
Facts
● The intestinal barrier is equipped with a multilayer
defence system working both simultaneously and
sequentially to protect against intrinsic and
extrinsic noxae.
● Inﬂammation is essential for epithelial barrier
protection but when uncontrolled, it can also
damage the tissue.
● Wound healing and inﬂammation are inter-
connected processes.
● Pre-mRNA splicing alterations are associated with
intestinal pathologies.
Open Questions
● Which molecular events or perturbations induce
disequilibrium of the intestinal barrier and the
establishment of chronic inﬂammation?
● How can we translate information from the latest
microbiome studies on immune function into
therapies?
● Can resolution be promoted in chronic intestinal
inﬂammatory disorders to halt inﬂammation?
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● Is targeting pre-mRNA alternative splicing a
potential therapeutic option to promote resolution
and epithelial barrier repair?
Introduction
Epithelial organs, such as the skin, respiratory and
gastrointestinal tracts, constitute a large fraction of the
body that interface with the external environment (esti-
mated surface areas of 1.7, 40 and 32m2, respectively)1–3.
Owing to their location, they encounter a variety of
assaults, e.g. from pathogens, biological or chemical
insults. However, in most cases the organism preserves
the integrity of these barriers and thereby prevents a state
of chronic inﬂammation.
Besides building a physical layer, numerous epithelial-
and non-epithelial cell types complement each other to
form a multi-layered, highly dynamic physical, bio-
chemical and immunological protection to maintain tis-
sue homeostasis4 (Fig. 1 and Table 1). Importantly, this
barrier system has to be selectively permeable to allow the
absorption of water and nutrients, while continuously
impeding harmful noxae. In most cases, the barrier
remains intact, which avoids the induction of uncon-
trolled inﬂammatory responses. However, in some
instances, the barrier is breached, leading to an inﬂam-
matory response to expel the invading noxae.
The multiple and redundant lines of defence that have
developed during evolution to maintain the barrier
highlights the selective pressure of investing energy to
prevent disruption of the barrier in the ﬁrst place. This
strategy of prevention, instead of constantly mounting an
inﬂammatory response to expel the insult, is energetically
economical for the host5–7. Indeed, although the inﬂam-
mation process commonly leads to the clearance of the
harmful noxae, tissue damage can also occur from per-
sistent or uncontrolled inﬂammation, requiring the host
to expend further energy to repair and restore barrier
integrity and function. Inﬂammation is a complex process
affecting not just the immune system but also physiolo-
gical processes such as induction of the acute-phase
response and fever, thus affecting multiple organs and
functions8. Initially, the inﬂammatory response acts
locally to eliminate the insulting agent and restore barrier
function (Fig. 2a). However, high noxae load and sus-
tained barrier damage may also activate systemic inﬂam-
matory responses (Fig. 2b). An initial localised response to
the noxae instead of a systemic reaction is more beneﬁcial
both at a metabolic energy level but also to prevent
unnecessary systemic inﬂammation that is accompanied
by fever, pain, anorexia and somnolence8.
In this review, we focus on the intestines as a model
epithelial barrier to highlight the importance of barrier
integrity for host ﬁtness. We discuss how inﬂammation
affects the barrier on multiple levels, and stress the
importance of resolution (i.e. the active host mechanism
to terminate inﬂammation)8–10. While the complexity of a
multi-layered protection system makes the barrier more
resistant to damage and infection, restoring barrier
integrity and function in the context of chronic inﬂam-
mation proves to be a challenging task.
Since intestinal barrier integrity is critically dependent
on intestinal epithelial cell (IEC) ﬁtness, mechanisms
affecting IEC function are important parameters that
regulate the epithelial barrier. Evidence for the essential
relevance of the epithelial barrier is further supported by
animal models in which targeted deletion of key IEC
components increased susceptibility to colitis develop-
ment11–13. Since proteins are the means for a cell to carry
out its functions, upstream processes such as post-
transcriptional modiﬁcations can alter cell function. For
instance, pre-mRNA alternative splicing (AS) generates a
variety of proteins from the same transcript, resulting in
proteins of complementary or even opposing functions14.
Indeed, dysregulation of AS has recently been linked to
barrier defects15,16. We therefore discuss the impact of AS
for intestinal health and pathology. Finally, we discuss
combined approaches to target inﬂammation, resolution
and barrier repair to treat chronic intestinal inﬂammation.
The Barrier’s Toll: detecting harmful noxae
Intestinal commensals exist in symbiosis with the host,
with both beneﬁting from the metabolic energy sources
provided reciprocally17,18. However, when barrier integ-
rity is compromised (Fig. 2), intestinal microbes (both
opportunistic commensals and pathogens) and microbial-
derived products have direct access to the inner mucosa
and blood vessels, posing a risk for systemic infections. A
key step in containing the infection and mitigating sys-
temic dissemination is the induction of inﬂammation to
eliminate the damaging insult, resulting in clearance and
neutralisation of harmful noxae along with subsequent
barrier repair. ECs and innate immune cells (such as
tissue-resident macrophages and dendritic cells) sense
microbial signals both directly from the microbes and
factors released by infected cells (pathogen-associated
molecular patterns; PAMPs) via evolutionarily conserved
pattern recognition receptors (PRRs), thereby initiating an
inﬂammatory cascade inducing the secretion of cytokines
and chemokines for the recruitment of myeloid immune
cells19.
IECs are among the ﬁrst responders to microbes and
express a wide range of PRRs ranging from extracellular
and endosomal membrane-bound Toll-like receptors
(TLRs) to cytoplasmic RIG-I-like receptors (RLRs) and
NOD-like receptors (NLRs)20, which enable the detection
of microbial molecules. Yet, ligation of PRRs on IECs do
not always result in inﬂammation activation - there is a
selective inhibition or initiation of inﬂammation
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depending on whether the PRR-stimuli originates from
their apical or basolateral sides, respectively21,22. In par-
ticular, TLR5 is speciﬁcally expressed on the basolateral
side of IECs, permitting responses to bacterial ﬂagellin of
invasive, epithelial-translocating bacteria (e.g. Salmonella)
but not commensal Escherichia coli, which does not
translocate21. Furthermore, in vivo rectal administration
of ﬂagellin into mice with injured colonic mucosa but not
intact mucosa led to mitogen-activated protein kinase 1/2
(MEK1/2) activation downstream of TLR5 signalling,
indicating that commensal-derived ﬂagellin can serve as
pro-inﬂammatory stimuli in injured intestines22. This
anatomical segregation of inﬂammation signalling is
advantageous to prevent uncontrolled inﬂammation
against commensal microbes, while permitting inﬂam-
mation only when microbes inﬁltrate into the sterile
compartments, indicative of damage in the epithelial
barrier and the need to repair it.
Inﬂammation can also be induced by non-microbial
stimuli, such as sterile cellular damage (i.e. transformed
cells, physical damage, UV-irradiation on the skin), which
eventually initiates wound repair23. Damage-associated
molecular patterns (DAMPs), similarly to PAMPs, possess
conserved molecular patterns recognised by PRRs
expressed by ECs and several other cell types at mucosal
sites. DAMPs are often intracellular components (e.g.
nucleic acids, ATP) which are released by damaged or
necrotic cells23. Alarmins, which include interleukin (IL)-
33 and IL-1α, are a subset of DAMPs with chemotactic
and activating functions on immune cells to clear
damaged or necrotic cells or amplify immune func-
tion23,24. How a cell dies inﬂuences the inﬂammatory
responses - controlled apoptotic death is self-containing
and typically less inﬂammatory, unless apoptotic cell
clearance is impaired.
Asides from released intracellular DAMPs, damaged or
transformed ECs also upregulate cell surface stress ligands
such as retinoic acid early inducible-1 (RAE-1; in mice) or
MHC class I-related protein A (MICA; in humans)25,26.
Upregulation of these stress ligands activate natural killer
(NK) receptors such as natural killer group 2D (NKG2D)
expressed on intraepithelial lymphocytes (IELs). Activated
IELs then kill stressed ECs and release pro-inﬂammatory
cytokines, such as tumour necrosis factor (TNF) and
interferon (IFN)γ27. Considering that microbial stimuli
and epithelial damages are themselves able to induce
inﬂammation, it is essential that both the damaging noxae
is cleared and that the barrier is repaired to prevent the
establishment of a chronic inﬂammatory condition.
Commensal stimuli promote barrier repair
Although microbial stimuli are best known to induce
intestinal inﬂammation, commensal-derived products
(including metabolites) and PRR-signalling also maintain
Fig. 1 Geographical layers of intestinal (colon) defence mechanisms. The epithelial barrier consists of multiple layers of defence, which function
both simultaneously and subsequently with each other. Geographically, from the outside (lumen) towards the inside (lamina propria): (1) the outer
most layer consists of mucus which acts as a physical barrier (2) that is further reinforced biochemically with antimicrobial peptides and
immunoglobulin A. (3) Intestinal epithelial cells form a single-cell layer of protection which is interspersed with intraepithelial lymphocytes. (4) Within
intestinal crypts are intestinal epithelial stem cells, which are key in replenishing the epithelial surface. (5) Beyond the epithelial layer is the lamina
propria, which is densely populated with leukocytes that serve to back up the innate immune defences and provide immunological memory against
future repeated insults. Note that this graphic does not dictate the order of importance but rather serves to visualise the multiple layers of defence
that make up the epithelial barrier. Abbreviations: Immunoglobulin A, IgA; intraepithelial lymphocyte, IEL; intestinal epithelial cell, IEC; intestinal
epithelial stem cell, IESC. Figure adapted from stock images provided by Servier (https://smart.servier.com/smart_image/)
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Table 1 Important players in the maintenance of the intestinal epithelial barrier at steady-state
Component Mode of protection References
Specialised secretory ECs
Paneth cells Secretion of antimicrobial peptides and factors supporting intestinal
stem cells
20
Goblet cells Secretion of mucins
Sentinel Goblet cells Speciﬁcally found at intestinal crypt entrance to protect the intestinal stem
cells niche: respond to invading microbes and induce mucus secretion by
neighbouring Goblet cells to expel bacteria
79
Mucus; consists of two dynamic layers in the large
intestine, a single loose layer in the small intestine
Physical and biochemical barrier 48,144
Outer layer Contains (commensal) bacteria that provide colonisation resistance, degrade
nutrients for host absorption
Inner layer Sterile compartment: contains secreted IgA, antimicrobial peptides
Secretory immunoglobulin A (sIgA) Natural IgA provide immune exclusion of microbes from the epithelium and
prevents over-stimulation of the mucosal immune system
49,145
Induction is dependent on microbes
Commensal-complexed sIgA reduce inﬂammatory cytokine levels (IL-8, TNF,
IL-1β)
146
High-avidity pathogen-speciﬁc IgA: clusters fast replicating bacteria for
subsequent clearance by the natural peristaltic ﬂow of intestinal contents
147
Prevents interaction with IECs and unnecessary inﬂammation
Antimicrobial peptides Directly kill or inhibit microbial growth 148
Immune cells Immunity against pathogens
Dendritic cells (DCs) Found in the lamina propria below the epithelium
Sample for luminal antigens via transepithelial dendrites 19
Promote intestinal repair 46
Intraepithelial lymphocytes Located in the epithelium 149
TCRγδ+ Secrete factors (e.g. TGFβ1, TGFβ2, KGF) to support & maintain the epithelial
barrier
TCRαβ+ Have cytotoxic activity
Innate lymphoid cells Found in the lamina propria below the epithelium 95
Action via IL-22 which promotes intestinal tissue repair, protects from
intestinal pathogens and restricts particular microbiota
Macrophages Sample luminal content, engulfment of invading bacteria and apoptotic
cells and maintain epithelial integrity
150
Commensal microbiota Provide colonisation resistance 151
Break down complex diet molecules for host uptake
Bacterial-derived stimuli from the luminal-side provide signals for the
epithelial barrier maintenance
30,92
Educate the mucosal immune system 152
DCs dendritic cells, ECs epithelial cells, IgA immunoglobulin A, sIgA secretory IgA, TNF tumour necrosis factor, TGF transforming growth factor, KGF keratinocyte growth
factor, TCR T cell receptor, IL Interleukin
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and facilitate repair of the epithelial barrier28,29. In sup-
port of PRR-signalling importance for both sensing noxae
and to initiate barrier repair, mice deﬁcient in myeloid
differentiation primary response 88 (Myd88), which
encodes a key downstream adaptor protein of all TLR
[except TLR3 that signals exclusively via TIR-domain-
containing adapter-inducing interferon-β (TRIF/TICAM-
1)], are susceptible to experimental colitis induced by
dextran sodium sulfate (DSS), a chemical that damages
the colonic epithelium30. This was in part due to the
reduced proliferation of the IECs following DSS-triggered
damage thereby diminishing barrier repair30. Defective
MyD88-signalling speciﬁcally in IECs reduced host sur-
vival in the Helicobacter hepaticus-induced model of
colitis, suggesting a key role of TLR-sensing by IECs for
barrier restoration31.
Since IECs express a range of TLRs, albeit at lower
expression levels than leukocytes32–39, it is conceivable
that TLR-signalling in IECs is directly responsible for
initiating the above-mentioned damage-induced secretion
of IL-6, TNF and CXCL1 to promote IEC repair. Further
underlying the importance of IEC-speciﬁc TLR-sensing,
the MyD88-downstream activation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)
maintains IEC proliferation and survival40,41. Defective
NF-κB signalling in IECs due to deletion of NF-κB
essential modulator (NEMO) increases TNF-induced
apoptosis, thus resulting in spontaneous chronic
intestinal inﬂammation in mice42. Supporting the need to
regulate TNF-induced death in the intestines, IECs
express Caspase-8 to protect them from TNF-induced
death and to regulate their turnover rate, as exempliﬁed
by the development of ileitis in IEC-speciﬁc Caspase-8
deﬁcient mice43.
Asides from IEC-mediated TLR-sensing, NF-κB signal-
ling is also important for immune function, also in the
intestine44,45. Particularly, in the DSS-colitis model,
MyD88-signalling in B cells (and to a lesser extent in
CD11c+ dendritic cells) is critical to promote intestinal
repair46. However, in the H. hepaticus-colitis model,
MyD88-activation within innate cells leads to worse
intestinal inﬂammation31. However, this effect is likely
speciﬁc to this pathogen as MyD88-signalling is protective
during infection with other intestinal pathogens, includ-
ing Salmonella and Citrobacter rodentium47.
The barrier repair’s dependency on immune cells is
likely related to the need to both control commensal
outgrowth at the damaged site and to provide reinforced
protective factors, such as immunoglobulin A (IgA) to the
barrier defences to prevent further microbial invasion48,49
(Fig. 1). Important growth factors for ECs such as epi-
dermal growth factor (EGF) and amphiregulin (AREG) are
also secreted by resident or inﬁltrating immune cells50.
Commensals play a signiﬁcant role in developing the
mucosal immune system, inﬂuencing the intestinal bar-
rier’s homeostatic defences and turnover rate, intestinal
Fig. 2 Damaging and healing properties of inﬂammation at barrier sites. a Acute barrier damage induces an inﬂammatory response, which
starts as a localised response to help repair the barrier: (i) Damage and release of alarmins (e.g. IL-33) and (ii) localised inﬂammatory cytokine release
(e.g. IL-6 and TNF) activate tissue myeloid cells to clear harmful noxae and promote IEC proliferation; (iii) the inﬂammation phase is shadowed by a
resolution phase (iv) which successfully shuts down inﬂammation and permits the restoration of the barrier. b Chronic inﬂammation induces further
barrier damage: (v) If inﬂammation becomes uncontrolled, this creates a pro-inﬂammatory microenvironment due to the increased cytokine release
and leukocyte inﬁltration, (vi) increased barrier disruption occurs due to the actions of pro-inﬂammatory leukocytes leading to (vii) systemic
involvement of the immune system and chronic inﬂammation at the barrier. Abbreviations: Intestinal epithelial cell, IEC; damage-associated
molecular patterns, DAMPs; pathogen-associated molecular patterns, PAMPs; interleukin-33, IL-33; interleukin-6, IL-6; tumour necrosis factor, TNF.
Figure adapted from stock images provided by Servier (https://smart.servier.com/smart_image/)
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inﬂammation and pathologies, which has been the topic of
several recent reviews51–53.
Inﬂammation alters the epithelial barrier
Once the epithelial barrier has been breached by
pathogens or by physical or chemical insult, PAMPs/
DAMPs activate IECs to secrete chemokines (e.g. che-
mokine ligand 20; CCL20), and tissue-resident myeloid
cells to secrete lipid-derived mediators (e.g. pros-
taglandins and leukotrienes). CCL20 gradients attract
chemokine receptor 6 (CCR6)-expressing immune cells
including dendritic cells, neutrophils and macrophages,
which survey the epithelium for noxae54. Additionally,
lipid-derived mediators are potent chemo-attractants of
neutrophils55,56 which are recruited to clear harmful
insults. During the inﬂammatory process, inﬁltrating
neutrophils migrate through the epithelium, temporarily
disrupting the epithelial barrier by breaking IEC inter-
cellular junctions56. This barrier disruption has been
shown in the lungs to provide stimuli for increased EC
proliferation via β-catenin signalling, and thereby pro-
mote later barrier repair57. Such integrated response of
barrier disruption to allow neutrophil transmigration
while simultaneous signalling to increase barrier repair
exempliﬁes the dynamic nature of the epithelial barrier
and the relevance of a prompt restoration of the barrier.
Within the tissue, neutrophils exert their characteristic
functions of phagocytosis, neutrophil extracellular trap
formation, and the degranulation of antimicrobial pro-
teins, reactive oxygen species and cytokines to ensnare
and eliminate the harmful noxae58. Cytokines and che-
mokines secreted by both IECs and myeloid immune cells
within the damaged site help create an inﬂammatory
milieu conducive to the clearance of the damaging noxae.
Cytokines secreted during intestinal damage such as IL-6,
TNF and chemokine C-X-C motif ligand 1 (CXCL1, also
known as KC-1) have dual roles on different cell types
(Fig. 2): promoting tissue repair by the regulation of IEC
proliferation, yet also acting as pro-inﬂammatory factors
on immune cells30. These inﬂammatory mediators act
locally to further activate macrophages and neutrophils in
the damaged tissue, but they may also induce the acute-
phase response in the liver, and the subsequent symptoms
of fever and fatigue if produced in larger quantities8.
Inﬂammation’s detrimental impact on different
cell types in the intestinal epithelium
Loss of barrier integrity through impairment of inter-cellular
interactions
The local inﬂamed intestinal microenvironment con-
sisting of recruited leukocytes and high local concentra-
tions of cytokines have beneﬁcial noxae-clearing and
support IEC proliferation in epithelial barriers but may
also contribute to a leaky barrier when excessive.
Inﬂammatory cytokines such as TNF and IFNγ can dis-
rupt the epithelial barrier by downregulating tight junc-
tions (claudin-1, occludin, zonula occludens protein-1)59
and adherens junctions (E-cadherin) in IECs63, thereby
compromising the physical barrier, one of the key “layers
of defence” (Fig. 1). This in turn reduces the epithelium
tightness and impairs the architecture of the intestinal
crypt, particularly in the colon60. Such increased sus-
ceptibility of the colonic crypt may be related to the
reduced cell-cycling rate of the intestinal epithelial stem
cells (IESCs) present in the colon compared to the small
intestines61. This may explain why the colon shows
reduced capability to replenish its crypts. Besides this
impact on the epithelial tightness and architecture, E-
cadherin loss in IECs also compromises the maturation
and positioning of goblet cells and Paneth cells, further
impairing mucus production and increasing susceptibility
to bacterial infection60. Paneth cells not only secrete
antimicrobial peptides, but also various growth factors
supporting and regulating IESCs in the intestines62. These
include EGF, transforming growth factor α (TGFα), Wnt
family member 3 (Wnt3) and Notch-ligand delta like 4
(Dll4)63. As the IESC niche is a source for EC replenish-
ment of the epithelial barrier (and thereby serves as one of
the deeper layers of defence by virtue of its epithelial
maintenance function; Fig. 1), excessive inﬂammation-
induced damage to the IESC niche can severely impair
function and architecture. Indeed, colon shortening is
macroscopically observed in highly inﬂamed mouse
intestines64 and narrowing in chronically inﬂamed human
intestines65.
Impact of inﬂammatory cues on IEC function via perturba-
tion of intracellular processes including pre-mRNA AS
Inﬂammation not only impacts inter-cellular con-
nectivity (e.g. downregulation of tight junctions) but also
promotes intracellular changes such as DNA methylation
and post-transcriptional modiﬁcations66–68. In particular,
alterations of mRNA splicing has been described in
inﬂammatory bowel disease (IBD), both within IECs69 and
leukocytes70. The main regulator of AS in ECs is the
epithelial splicing regulatory protein 1 (ESRP1) which
maintains the epithelial identity of a cell and regulates
epithelial-to-mesenchymal transition15,71,72. ESRP1 is
conserved across species16 and deletion of Esrp1 in mice
results in lethal morphological defects in the skin and
craniofacial malformation15.
In support of ESRP1-mediated AS’s role in epithelial
barrier integrity, we recently showed that the intestinal
barrier integrity of mice with dysregulated Esrp1 function
is compromised16. Speciﬁcally, mutant mice with altered
ESRP1 function show reduced barrier integrity and
translocation of commensals to the mucosa, resulting in
increased susceptibility to DSS-colitis. This phenotype in
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Esrp1 mutants was mediated by reduced proliferative
capacity of IECs16. Additionally, we found that inﬂamed
biopsies of IBD patients have lower ESRP1 transcript
levels compared to matched non-inﬂamed tissue16. In
corroboration with this, mice with double knock-outs of
Esrp1 and its paralog Esrp2 in the epidermis have defec-
tive tight junction proteins73. Based on these data, we
propose that AS controls intestinal barrier integrity via
modulation of tight junction proteins and regulation of
proliferative capacity of IECs, which if dysregulated pre-
disposes the host to chronic inﬂammation and associated
tissue damage.
Role of microbe-derived cues on IECs as an addition to host-
released inﬂammatory molecules
In the intestines, commensal bacteria ferment dietary
ﬁbres into short-chain fatty acid (SCFA) metabolites such
as butyrate, acetate and propionate74 which are recog-
nised directly by IECs via receptors such as GPR41/
GPR4375. SCFAs serve as important energy sources of
ATP for colonocyte function76,77. However, in chronic
inﬂammation, with increasing epithelial damage and
erosion of the crypts, butyrate can more easily reach the
IESC niche. Although butyrate provides IECs with
energy, it has inhibitory effects on IESC proliferation and
EC replenishment78. During homeostasis, differentiated
colonocytes (positioned further away from the crypts)
metabolise butyrate, thereby decreasing its concentration
towards the crypts and preventing the inhibition of IESC
proliferation78. This exclusion of the inhibitory butyrate
from IESCs is particularly relevant in the context of
epithelial repair when there is a need for IESC pro-
liferation at an increased rate. As the IESC niche plays an
important role in epithelial maintenance, this site is
protected by specialised sentinel goblet cells (SenGCs)
located at the colonic crypts’ entrances79. SenGCs trigger
neighbouring goblet cells to increase mucus production
following TLR-activation in an effort to control microbial
inﬁltration79. However, since inﬂammation can compro-
mise goblet cell maturation and positioning60, this
mechanism is compromised in protecting the IESC dur-
ing inﬂammation.
Altogether, inﬂammatory damage in the epithelial sur-
face may reach the IESC niche and thereby lead to a
chain-reaction of barrier impairments and chronic
inﬂammation in the intestines. While the integrated
protective mechanisms of the intestinal barrier are
advantageous to prevent (mild) damage and infection in
the ﬁrst place, a multi-hit disruption on multiple layers of
defence (Fig. 1) - e.g. as it occurs during chronic inﬂam-
mation (Fig. 2b) - makes it challenging to re-establish
homeostatic balance.
Inﬂammation-induced microbial dysbiosis
Inﬂammation-induced intestinal barrier damage often
perturbs the symbiotic relationship between commensals
and the host. Inﬂammation alters the intestine’s oxidative
and metabolomic environment - factors which the com-
mensals are dependent upon for their survival and
growth80. This generally involves a deviation of the com-
mensal population from a healthy, diverse symbiotic proﬁle
into a ﬂora with typically reduced complexity and over-
representation of particular taxa of microbes77,81. Pertur-
bations to the structure of commensal microbial commu-
nities, referred to as dysbiosis, is frequently observed in
intestinal immunopathologies such as IBD81–83 but also in
other diseases with barrier dysregulation such as cancer84,85,
allergies86, obesity87 and graft-vs-host disease88,89.
Commensals contribute to the overall intestinal barrier
maintenance via their fermentation products such as
SCFAs, which act as stimuli for IECs90–92. In line with
this, IBD patients with a compromised intestinal barrier
integrity have alterations in SCFA-producing bacteria83. It
is therefore conceivable that inﬂammation-mediated
dysbiosis can further compromise the barrier integrity as
the crosstalk between commensals, IECs and mucosa-
associated immune cells becomes dysregulated55.
The conundrum of whether dysbiosis precedes inﬂam-
mation or vice versa is that it is likely that they are
interdependent events. Studies have shown that inﬂam-
mation alters the intestinal environment thereby reshap-
ing microbial populations, yet gnotobiotic animal studies
have also implicated that dysbiosis can predispose animals
towards intestinal inﬂammation. This quasi philosophical
question is further elaborated on in a review by Ni et al.
which summarises IBD and dysbiosis associations80.
Inﬂammation and excessive (adaptive) immune
activation
Apart from alterations to IECs and the commensal
community structures, barrier damage can also alter yet
another layer of defence, the mucosal immune system
(Fig. 1). The mucosal immune system, the commensal
microbiome and the IECs form a tripartite network in the
intestines - interacting with each other for growth factors
and signals beneﬁcial for their development93–95. The
intestine is the largest immunological organ harbouring
many tissue-resident immune cells throughout its
length96,97.
In the context of uncontrolled or chronic inﬂammation,
the pro-inﬂammatory microenvironment and the
damaged barrier perpetuate constant immunological
activation and recruitment of immune cells through sus-
tained exposure to microbial signals. Inﬂamed tissues of
IBD patients show increased inﬁltration of leukocytes
from both the innate and adaptive immune system (Fig.
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2b)98. IBD is a heterogeneous disease, in the inﬂamed
mucosa of Crohn’s disease (CD) patients, inﬂammation is
most commonly driven by pathological T-helper cells 1
(Th)1/Th17 responses and their associated cytokines,
IFNγ and IL-17 respectively. However, in ulcerative colitis
(UC) Th2 cells and their signature cytokines IL-4 and IL-
13 predominate99. As Th1/Th2/Th17-derived cytokines
have been shown to inhibit the stem cell renewal of IESCs
and their direct differentiation into Paneth cells (Th1/
IFNγ-induced) or Tuft cells (Th2/IL-13-induced)100, it is
conceivable that these cytokines further impair epithelial
repair during IBD. In contrast, IL-10 from regulatory
T cells (Tregs) promote stem cell renewal100.
Post-inﬂammatory healing: the restorative side of
inﬂammation
Damage and loss of epithelial architecture are unwanted
side-effects of chronic inﬂammation. However, in most
instances, inﬂammation is self-limiting and is overall
beneﬁcial for the host in preventing infections, as sug-
gested by the evolutionarily conservation of multiple
pathways of inﬂammation in different taxonomic
clades101–103. Inﬂammation is critical for adapting to
intrinsic and extrinsic challenges. Yet, for inﬂammation to
be beneﬁcial, it has to be properly regulated.
Resolution shadows inﬂammation for a balanced
and beneﬁcial host response
The role of resolution (=restoration to homeostasis) is a
rather neglected aspect of inﬂammation10 that is distinct
from immunosuppression (=dampening inﬂammation-
sustaining events). Despite inﬂammation onset being
recognised to be an active and controlled process, the
resolution phase has mistakenly been assumed to be a
passive process in which inﬂammation simply wanes.
Rather, simultaneously with the active down-regulation of
inﬂammation, resolution is actively promoted by specialised
pro-resolving lipid mediators (SPMs) which include mar-
esins, resolvins, protectins and lipoxins, produced as a result
of enzymatic cleavage of omega-3 (ω-3) and ω-6 dietary
essential polyunsaturated fatty acids (PUFA)104. Endogen-
ously, ω-3 and ω-6 PUFA are incorporated into the cellular
membranes of all tissues where they can be utilised for
transformation into pro-inﬂammatory (e.g. prostaglandins
and leukotrienes) lipids or pro-resolution SPMs105,106.
SPMs have short half-lives and act in an autacoid
manner104. They are secreted by many cell types found in
the inﬂammatory environment (neutrophils, monocytes,
macrophages, innate lymphoid cells, ECs and platelets)
therefore providing a spatio-temporal control of inﬂam-
mation104,107. Appropriate spatio-temporal synthesis and
action of SPMs is key to balancing the beneﬁts of
inﬂammation for clearance of harmful antigen and the
prevention of tissue damage.
As inﬂammation progresses and damage signals
decrease, progressive “class-switching” of lipid mediators
from the pro-inﬂammatory prostaglandins and leuko-
trienes into pro-resolving lipoxins occur108. SPMs subse-
quently halt neutrophils from inﬁltrating into the
inﬂamed site as the damage signal is cleared109 while
promoting the survival of IECs110,111, the production of
antimicrobial peptides by IECs110,112, increased phagocy-
tosis of bacteria and apoptotic cells by macrophages113,
efferocytosis (macrophage-mediated clearance of apop-
totic neutrophils which came into the damaged site to
clear the harmful antigens)114,115, and the secretion of
anti-inﬂammatory IL-10114. These concerted effects serve
to enable barrier restoration and critically act beyond the
initiating events of inﬂammation.
While SPMs are important players in initiating resolu-
tion, other mechanisms work synchronously to repair the
barrier. IL-33 and its receptor ST2 are up-regulated
immediately following DSS-colitis and during the intest-
inal barrier recovery phase, which promotes intestinal
wound healing in mice116. Other cytokines which limit
intestinal inﬂammation and maintain tissue homeostasis
are IL-10 and IL-22, both members of the IL-10 cytokine
family95,117. Furthermore, direct effects of growth factors
such as EGF and transforming growth factor β (TGFβ) on
IECs for increased proliferation9 and increased mucus
production from goblet cells118 act to both replenish and
reinforce the barrier (Fig. 3).
Through the orchestrated effort of halting inﬂammation
and turning on wound healing processes, SPMs along
with other resolution mediators promote the intestinal
barrier’s recovery and the return to tissue homeostasis.
Not all repairs are successful
Barrier repair is clearly beneﬁcial to stop the uncon-
trolled inﬁltration of harmful noxae. However, repair of
the intestinal barrier can vastly differ in its success fol-
lowing self-limited inﬂammation versus dysregulated
chronic inﬂammation. In the best-case scenario of self-
limited inﬂammation, the following steps occur for timely
barrier restoration: (1) inﬂux of neutrophils with localised
action, (2) harmful antigen clearance, (3) resolution acti-
vation, (4) clearance of inﬁltrating neutrophils and pro-
inﬂammatory milieu by macrophages, (5) macrophage
death and clearance, (6) wound repair (see also Fig. 3).
However, in scenarios of chronic inﬂammation, several
of these steps are compromised. A side-effect of tissue
repair in a chronically inﬂamed tissue is the development
of ﬁbrosis and scarring119, which can impair normal tissue
function due to the loss of elasticity and healthy structure.
Intestinal ﬁbrosis develops due to the excessive produc-
tion of extracellular matrix (ECM) by activated
mesenchymal cells leading to luminal narrowing. This is
one of the main indication for surgery in CD patients, and
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post-surgery disease recurrence is common120. While
various inﬂammatory cytokines such as TGFβ and IL-13
promote intestinal ﬁbrosis, it is not certain if there are
also inﬂammation-independent mechanisms that trigger
ﬁbrogenesis121. In particular, anti-inﬂammatory drugs
only marginally impact on ﬁbrosis121. ESRP1-mediated AS
may also play a role in ﬁbrogenesis by modulating
epithelial-to-mesenchymal transition (EMT), a process
that occurs during embryonic development but is also
important for wound healing, ﬁbrosis and cancer
progression122. In vitro silencing of ESRP1/2 led to a
mesenchymal-like splicing signature, cellular morphology
and motility thereby establishing the basis for generating
repair/ﬁbrosis-associated mesenchymal cells71,72.
In addition to tissue ﬁbrosis and scarring resulting from
continuous damage occurring in the inﬂamed tissue, cell
death becomes an additional inﬂammatory stimulus.
Although apoptosis is a programmed cell-death process,
in the case where increased apoptosis rate is not balanced
by a corresponding higher clearance of apoptotic bodies,
Fig. 3 Combining strategies to target inﬂammation, resolution and epithelial barrier repair. a Dampening the inﬂammatory response in the
damaged barrier is critical to allow resolution mechanisms to take place. Current therapeutics for intestinal inﬂammation (e.g. IBD) utilise anti-
inﬂammatory and/or anti-migratory drugs. b The resolution phase involves conversion of pro-inﬂammatory lipid mediators such as leukotrienes and
prostaglandins into specialised pro-resolution mediators such as resolvins. In addition, other cytokines such as IL-22 and IL-10 help to further dampen
inﬂammatory responses while IL-33 and growth factors such as EGF promote IEC repair. Future therapeutic interventions may foster resolution by
using pro-resolving factors or synthesised mimetics. Promotion of IEC repair and maintenance could also be enhanced by targeting speciﬁc splicing
isoforms or via the application of bacterial-derived metabolites as their speciﬁc cellular targets and mode of action become better delineated (c).
Combination of anti-inﬂammatory treatments with therapeutic promotion of resolution and epithelial barrier repair restores a functional barrier to
prevent further inﬂammation. Areas for therapeutic manipulations are indicated by blue text and arrows. Abbreviation: alpha-4 beta-7 integrin, α4β7;
epidermal growth factor, EGF; interferon γ, IFNγ; interleukin 6, IL-6; interleukin 10, IL-10; interleukin 22, IL-22; interleukin 33, IL-33; intestinal epithelial
cell, IEC; macrophage, Mφ; maresin 1, MaR1; nuclear factor kappa-light-chain-enhancer of activated B cells, NF-κB; omega-3, ω-3; resolvin E1, RvE1;
specialised pro-resolving lipid mediators, SPM; tumour necrosis factor, TNF. Figure adapted from stock images provided by Servier (https://smart.
servier.com/smart_image/)
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secondary necrosis of these apoptotic bodies may occur
which releases potentially toxic intracellular contents into
the inﬂamed milieu123.
Proper timing of pro-resolving SPM synthesis and
action is critical to enable both an effective inﬂammatory
response to occur while preventing excessive tissue
damage. As SPMs are produced by transcellular bio-
synthesis and are rapidly degraded in the local environ-
ment by myeloid cells124, chronic inﬂammatory
conditions speed up the degradation of SPMs. Therefore,
while the rapid degradation of SPMs by myeloid cells is
beneﬁcial to allow an inﬂammatory response to occur, the
instability of SPMs becomes an issue in conditions of
uncontrolled inﬂammation.
Negotiating peace at the intestinal barrier:
current therapeutics and outlook
In the context of infections, inﬂammation resolution
occurs following the clearance of the pathogen. However,
in chronic inﬂammatory diseases such as IBD, with
undeﬁned aetiology, it is difﬁcult to determine the nature
of the initiating damaging insult, and therefore how to
clear it - both from the viewpoint of the immune system
and for therapeutic intervention. Current knowledge on
IBD indicates there are genetic contributions such as
nucleotide-binding oligomerization domain-containing
protein 2 (NOD2) mutations which affect downstream
NF-κB signalling (key protein complex for immune cell
activation) in myeloid immune cells125 or autophagy
related 16 like 1 (ATG16L1) mutations, which alter the
autophagosome pathway used to process intracellular
pathogens126. Genome-wide association studies (GWAS)
have additionally highlighted over 160 genetic risk loci for
IBD127 although the majority of the loci are in non-
protein coding regions of the genome128 and cluster
within the gene regulatory elements in both IECs and
immune cells129. However, environmental factors are also
strong contributors as IBD prevalence is highest in the
Western world. However, the current greatest increase in
IBD incidence is occurring in newly industrialised coun-
tries130. Despite its multi-factorial aetiology, a character-
istic of IBD is the disruption of the epithelial barrier,
which allows unrestricted interaction of the commensal
microbes with the IECs and the immune cells and
therefore contributes to the sustained mucosal inﬂam-
mation131. Repairing the barrier in IBD is therefore
important to prevent damage from spreading faster than
repair can occur.
As IBD is an immune-mediated disease, the focus of
many therapies for IBD have been on dampening
inﬂammation132. Current front-line therapy for IBD is the
use of general anti-inﬂammatory and immunomodulatory
drugs (Fig. 3a) including steroids, antibodies against
cytokines (e.g. anti-TNF, anti-IL-12, anti-IL-23) and
thioguanine nucleotides which suppress T cell respon-
ses9,133. However, only 50% of treated patients respond to
these drugs134. More localised therapies include targeting
leukocyte-expressed integrins (e.g. using anti-β7 and anti-
α4β7 antibodies) which bind to the mucosal addressin
cellular adhesion molecule-1 (MAdCAM-1) within the
intestines, thereby reducing inﬂammation135. The use of
these anti-integrin antibodies have a very strong safety
record and are particularly suited for IBD patients in
remission135. Despite these therapeutic options, many
patients still fail to respond, eventually lose response over
time or develop antibodies against the drugs136. Janus
kinase (JAK) inhibitors, which work by disrupting the
JAK-signal transducers and activators of transcription
(STAT) signalling pathway downstream of many cytokine
receptors, have recently been suggested for second-line
treatment of moderate to severely active UC, as they
improved outcomes by inducing remission and mucosal
healing136.
While these therapies mostly aim to dampen inﬂam-
mation, we propose that targeting SPMs and other reso-
lution mediators to promote resolution could be a
promising future option in addition to current regimens
(Fig. 3b), which also avoids general immune suppression
and the subsequent risk of opportunistic infections.
However, one of the challenges with utilising SPMs is the
rapid degradation by various cell types in the inﬂamed
tissue. Therefore, both delivery and/or increased protec-
tion against degradation have to be optimised in such
therapeutic options. Therapeutic administration of
PUFAs in DSS-colitis mouse models have shown to
reduce pro-inﬂammatory cytokines and NF-κB activa-
tion132,137,138. Importantly, SPM analogues with improved
inactivation-resistance have been synthetically produced
which shall enable further investigations into their
potential beneﬁts for the treatment of chronic intestinal
disorders139.
In conjunction to this, AS of pre-mRNA has not been
extensively studied in regard to intestinal inﬂammatory
conditions and intestinal ﬁbrosis, despite its biological
prevalence (more than 95% of multi-exonic human genes
undergo AS)140. We16 and others15,73 have shown that AS
is relevant for epithelial barriers both at homeostasis and
in pathologies. Indeed, serving as a proof of concept that
therapies correcting AS can work, the use of drugs which
act as splice-switching oligonucleotides141 is currently
approved for the treatment of spinal muscular atrophy142.
Microbiota studies in relation to human diseases are
currently heavily researched, yet the current goal is to
move away from correlation studies of perturbed com-
mensal communities to particular diseases towards a
functional understanding of how such changes impact
intestinal health. Ultimately, the hope is to identify key
molecules derived from microbes that can be used to
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promote resolution and barrier repair (Fig. 3b). Bacterial-
derived metabolites can be produced by gut bacteria from
dietary components (e.g. SCFAs which are generally anti-
inﬂammatory), synthesised de novo (e.g. polysaccharide A
which induces secretion of IL-10 from CD4+ T cells) or
are host-derived metabolites which are biochemically
modiﬁed by gut bacteria (e.g. taurine which enhances
epithelial barrier function)143. These molecules represent
yet another option for the modulation of inﬂammation.
Importantly, while dampening excessive uncontrolled
inﬂammation is often necessary to treat chronic inﬂam-
matory disorders, there should also be a combined focus
on the restoration of the epithelial barrier via resolution
mechanisms (Fig. 3). This combined effort of alleviating
disease and repairing the barrier may ultimately lead to
long-lasting effects that prevent relapsing inﬂammatory
conditions.
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